Praxis Medicines Files 8-K on Financials, Unregistered Equity Sales

TL;DR

**Praxis just filed an 8-K about its financials and selling new stock, watch for dilution.**

AI Summary

Praxis Precision Medicines, Inc. filed an 8-K on January 10, 2024, reporting events from January 4, 2024, related to its financial condition and unregistered sales of equity securities. This filing indicates that the company is actively managing its capital structure, which is crucial for investors as it can impact share dilution and future funding capabilities. The company's common stock, with a $0.0001 par value per share, is traded on The Nasdaq Global Select Market under the symbol PRAX.

Why It Matters

This filing signals that Praxis Precision Medicines is making moves regarding its financial health and potentially issuing new shares, which could dilute existing shareholder value or provide necessary capital for operations.

Risk Assessment

Risk Level: medium — The mention of 'Unregistered Sales of Equity Securities' suggests potential dilution for existing shareholders, which is a medium risk for stock value.

Analyst Insight

Investors should monitor subsequent filings for details on the 'Unregistered Sales of Equity Securities' to assess potential dilution and the use of proceeds, as this could impact share price and future growth prospects.

Key Numbers

• $0.0001 — Par value per share (The stated par value of Praxis Precision Medicines, Inc.'s common stock.)

Key Players & Entities

• Praxis Precision Medicines, Inc. (company) — the registrant filing the 8-K
• $0.0001 (dollar_amount) — par value per share of common stock
• January 4, 2024 (date) — date of earliest event reported
• January 10, 2024 (date) — date the 8-K was filed
• The Nasdaq Global Select Market (company) — exchange where Praxis common stock is registered

Forward-Looking Statements

• Praxis Precision Medicines, Inc. will likely provide more details on the 'Unregistered Sales of Equity Securities' in future filings. (Praxis Precision Medicines, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share PRAX The Nasdaq Glo
• $81.3 million — and cash equivalents were approximately $81.3 million. The cash and cash equivalents informa
• $22.5605 — ares"), to BCPE at a price per share of $22.5605 for an aggregate purchase price of $10,
• $10,000,009.31 — 5605 for an aggregate purchase price of $10,000,009.31. The per share price was based on a 20%

Filing Documents

• prax-20240104.htm (8-K) — 36KB
• 0001689548-24-000011.txt ( ) — 164KB
• prax-20240104.xsd (EX-101.SCH) — 2KB
• prax-20240104_lab.xml (EX-101.LAB) — 24KB
• prax-20240104_pre.xml (EX-101.PRE) — 13KB
• prax-20240104_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. Praxis Precision Medicines, Inc. (the "Company") is providing the following financial information. As of December 31, 2023, the Company's cash and cash equivalents were approximately $81.3 million. The cash and cash equivalents information above is based on preliminary unaudited information and management estimates for the year ended December 31, 2023, is not a comprehensive statement of the Company's financial results as of and for the fiscal year ended December 31, 2023, and is subject to completion of the Company's financial closing procedures. The Company's independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, this preliminary estimate. The information contained in this item is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.

02. Unregistered Sales of Equity Securities

Item 3.02. Unregistered Sales of Equity Securities. The information included in Item 8.01 below regarding the Stock Purchase Agreement (defined under Item 8.01) is incorporated by reference under this Item 3.02. The Shares (defined under Item 8.01) will be issued in reliance upon an exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), contained in Section 4(a)(2) of the Securities Act. BCPE (defined under Item 8.01) has represented that it is acquiring the Shares for investment purposes, and not with a view towards, or for offer or sale in connection with, any distribution or dissemination thereof, and appropriate legends will be affixed to the Shares.

01. Other Events

Item 8.01. Other Events. Collaboration and License Agreement with Tenacia Biotechnology On January 4, 2024, the Company entered into an exclusive collaboration and license agreement (the "Collaboration Agreement") with Tenacia Biotechnology (Shanghai) Company, Ltd. ("Tenacia"), a China-based portfolio company of Bain Capital focused on central nervous system drug development and commercialization. Under the Collaboration Agreement, Tenacia has agreed to develop and commercialize ulixacaltamide for the treatment of essential tremor in Greater China, including mainland China, Hong Kong, Macau and Taiwan. As part of the consideration for the Collaboration Agreement, the Company entered into a Stock Purchase Agreement (the "Stock Purchase Agreement") with BCPE Tenet Holdings Cayman, Ltd. ("BCPE") pursuant to which the Company issued and sold 443,253 shares of the Company's common stock, par value $0.0001 per share (the "Shares"), to BCPE at a price per share of $22.5605 for an aggregate purchase price of $10,000,009.31. The per share price was based on a 20% premium over the 30-day volume-weighted average price. PRAX-628 Update On January 8, 2024, the Company provided a business update on its portfolio. Regarding PRAX-628, the Company shared that a preliminary analysis of the 15 mg cohort of its Phase 2a Photo-Paroxysmal Response ("PPR") study exceeded the Company's expectations in terms of drug activity. The full data set for the PPR study will be disclosed after completion of the ongoing 45 mg cohort and full analysis of the study expected in the first quarter of 2024.

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K (the "Current Report") contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding the Company's future expectations, plans and prospects, including, without limitation, statements regarding clinical trials and clinical development of the Company's product candidates and the preliminary estimate of its cash and cash equivalents as of December 31, 2023, as well as other statements that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. The express or implied forward-looking statements included in this Current Report are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation uncertainties inherent in clinical trials; preliminary analyses from ongoing studies and trials differing materially from final data from preclinical studies and completed clinical trials; the expected timing of clinical trials, data readouts and the results thereof; submissions for regulatory approval or review by governmental authorities; and risks described in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, its Quarterly Reports on Form 10-Q and other filings made with the Securities and Exchange Commission. Although the Company's forward-looking SIGNATURE Pur

View Full Filing

View this 8-K filing on SEC EDGAR